Combining partial liver resection and local ablation of liver tumours: a preliminary Dutch experience

The combination of partial liver resection and radiofrequency ablation (RFA) is a novel concept in the treatment of unresectable liver malignancies. The aim of this study is to evaluate the results of this combined strategy in the Netherlands. Thirty-five patients treated with a combination of parti...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of surgical oncology Vol. 4; no. 1; p. 46
Main Authors Fioole, Bram, Jansen, Maarten C, van Duijnhoven, Frederieke H, van Hillegersberg, Richard, van Gulik, Thomas M, Borel Rinkes, Inne Hm
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 17.07.2006
BioMed Central
BMC
Online AccessGet full text

Cover

Loading…
More Information
Summary:The combination of partial liver resection and radiofrequency ablation (RFA) is a novel concept in the treatment of unresectable liver malignancies. The aim of this study is to evaluate the results of this combined strategy in the Netherlands. Thirty-five patients treated with a combination of partial liver resection and RFA were identified from a prospectively registered pooled multicentre database. All patients were operated between June 1999 and November 2003 in 8 medical centres in The Netherlands. Main outcome parameters were morbidity, mortality, local success rate, and survival. Thirty-seven operations were performed in 35 patients. The group consisted of 20 male and 15 female patients with a median age of 59 years (range 41-76). Seventy-six lesions were resected and RFA was performed to ablate 82 unresectable liver tumours. Twelve patients developed a total of 24 complications, resulting in an overall perioperative morbidity rate of 32%. In two patients major complications resulted in postoperative death (postoperative mortality rate 5.4%). Local success rate after RFA was 88% and the estimated 1-, 2- and 3-year overall survival rates were 84%, 70% and 43%, respectively. This strategy should only be performed following strict patient selection and within the context of prospective clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1477-7819
1477-7819
DOI:10.1186/1477-7819-4-46